Trusted Resource for Clinical Trials, Protocols & Progress
Crossover designs in biomarker-driven oncology trials allow patients to switch from the control arm to the experimental treatment (or vice versa) after certain conditions are met—often upon disease progression. These designs are particularly valuable in targeted therapy settings, where ethical considerations demand offering potentially beneficial treatments to all eligible participants.
Click to read the full article.
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases globally. Two of the most clinically significant biomarkers in NSCLC are the epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. Targeted therapies for these biomarkers have transformed treatment paradigms, offering improved progression-free survival (PFS) and overall response rates (ORR) compared to conventional chemotherapy.
Click to read the full article.
Basket trials represent a groundbreaking shift in oncology clinical research, particularly in the era of precision medicine. Unlike traditional cancer trials that focus on a single tumor type, basket trials enroll patients with different types of cancer who share a common molecular alteration. This tumor-agnostic approach enables simultaneous testing of a targeted therapy across multiple cancer types within a single study framework.
Click to read the full article.
Umbrella trials are an innovative clinical trial design in which multiple targeted therapies are evaluated simultaneously in a single disease setting, each therapy matched to a biomarker-defined patient subgroup. Unlike basket trials, which are tumor-agnostic, umbrella trials focus on a single tumor type but stratify patients into sub-studies based on molecular characteristics.
Click to read the full article.
Master protocols are overarching clinical trial frameworks designed to evaluate multiple therapies, diseases, or patient subgroups within a single coordinated trial structure. In oncology, master protocols often integrate the principles of basket and umbrella trials, enabling the efficient testing of targeted therapies across diverse patient populations.
Click to read the full article.
Master protocol trials are transforming oncology clinical research by enabling the simultaneous evaluation of multiple therapies and patient subgroups under a single, cohesive trial framework. These designs incorporate both basket and umbrella trial methodologies, offering unmatched adaptability in precision medicine.
Click to read the full article.
Basket trials represent a groundbreaking approach in oncology, allowing a single investigational drug to be tested across multiple tumor types that share a common molecular alteration. Instead of focusing on where the cancer originates, basket trials focus on the genetic or molecular signature of the tumor. This tumor-agnostic approach has already led to landmark drug approvals, such as TRK inhibitors for NTRK fusion-positive cancers.
Click to read the full article.
Umbrella trials are innovative multi-arm clinical trial designs that evaluate multiple investigational therapies within a single type of cancer, stratified by specific molecular or genetic biomarkers. Unlike basket trials, which test one drug across many tumor types, umbrella trials focus on tailoring treatment strategies within a single tumor type, such as non-small cell lung cancer (NSCLC), based on individual biomarker profiles.
Click to read the full article.
Hybrid basket and umbrella trials combine the strengths of two innovative oncology trial designs to maximize efficiency and scientific yield. While basket trials assess a single drug across multiple tumor types sharing a biomarker, umbrella trials evaluate multiple therapies within a single tumor type, stratified by different biomarkers. A hybrid design merges these approaches under a unified master protocol, enabling the simultaneous evaluation of multiple drugs across multiple tumor types and biomarker-defined subgroups.
Click to read the full article.
Immunotherapy has transformed the landscape of oncology by harnessing the patient’s own immune system to recognize and eliminate cancer cells. From checkpoint inhibitors to CAR-T cells and neoantigen vaccines, immuno-oncology (IO) therapies are expanding the arsenal against malignancies. However, these innovative approaches require specialized clinical trial designs to address unique biological, regulatory, and operational challenges.
Click to read the full article.
